TY - JOUR
T1 - Outcome prediction for symptomatic patients with fibroids who underwent uterine artery embolization
AU - Wu, Qingxia
AU - Motaghi, Mina
AU - Tang, Hao
AU - Hazhirkarzar, Bita
AU - Shaghaghi, Mohammadreza
AU - Ghadimi, Maryam
AU - Baghdadi, Azarakhsh
AU - Rezvani, Roya
AU - Mohseni, Alireza
AU - Borhani, Ali
AU - Madani, Seyedeh Panid
AU - Afyouni, Shadi
AU - Zandieh, Ghazal
AU - Kamel, Ihab R.
N1 - Publisher Copyright:
© 2023
PY - 2024/1
Y1 - 2024/1
N2 - Purpose: To predict the clinical outcome of symptomatic patients with uterine leiomyomas who underwent uterine artery embolization (UAE), based on clinical and radiological features. Methods: Patients with symptomatic uterine leiomyomas who underwent UAE from March 2010 to September 2019 were consecutively included in this retrospective study. Patients with persistent or recurrent symptoms and those who needed repeated UAE, myomectomy, or hysterectomy following the initial treatment were considered to have a poor outcome after UAE. The total and enhancing volume of the dominant leiomyoma in each location and uterine volume were obtained before and after UAE. Univariate and multivariate Cox proportional hazard analyses were used to evaluate the parameters that could predict poor outcome. Results: A total of 116 patients (mean age, 45 ± 5 years) were included. Forty-six patients (46/116, 39.7%) showed poor outcome. Cox regression analysis showed higher hazard of poor outcome for younger patients vs. older patients (HR: 0.92, p-value: 0.01), patients with adenomyosis vs. patients without adenomyosis (HR: 2.47, p-value < 0.01), patients with adenomyosis thickness > 2.5 cm before UAE vs. patients without adenomyosis (HR: 4.2, p-value < 0.01) and for patients with intramural fibroid enhancement volume > 440 cm3 compared to patients with no intramural fibroids (p-value: 0.06). Multivariate Cox regression analysis including age, the thickness of adenomyosis, and intramural leiomyoma volume of enhancement before UAE was chosen as the best model to predict the outcome. Conclusions: Pretreatment clinical and MRI features could identify patients with a higher risk for poor outcome after UAE.
AB - Purpose: To predict the clinical outcome of symptomatic patients with uterine leiomyomas who underwent uterine artery embolization (UAE), based on clinical and radiological features. Methods: Patients with symptomatic uterine leiomyomas who underwent UAE from March 2010 to September 2019 were consecutively included in this retrospective study. Patients with persistent or recurrent symptoms and those who needed repeated UAE, myomectomy, or hysterectomy following the initial treatment were considered to have a poor outcome after UAE. The total and enhancing volume of the dominant leiomyoma in each location and uterine volume were obtained before and after UAE. Univariate and multivariate Cox proportional hazard analyses were used to evaluate the parameters that could predict poor outcome. Results: A total of 116 patients (mean age, 45 ± 5 years) were included. Forty-six patients (46/116, 39.7%) showed poor outcome. Cox regression analysis showed higher hazard of poor outcome for younger patients vs. older patients (HR: 0.92, p-value: 0.01), patients with adenomyosis vs. patients without adenomyosis (HR: 2.47, p-value < 0.01), patients with adenomyosis thickness > 2.5 cm before UAE vs. patients without adenomyosis (HR: 4.2, p-value < 0.01) and for patients with intramural fibroid enhancement volume > 440 cm3 compared to patients with no intramural fibroids (p-value: 0.06). Multivariate Cox regression analysis including age, the thickness of adenomyosis, and intramural leiomyoma volume of enhancement before UAE was chosen as the best model to predict the outcome. Conclusions: Pretreatment clinical and MRI features could identify patients with a higher risk for poor outcome after UAE.
KW - Adenomyosis
KW - Leiomyoma
KW - Magnetic resonance imaging
KW - Uterine artery embolization
UR - http://www.scopus.com/inward/record.url?scp=85178557243&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85178557243&partnerID=8YFLogxK
U2 - 10.1016/j.clinimag.2023.110028
DO - 10.1016/j.clinimag.2023.110028
M3 - Article
C2 - 38039750
AN - SCOPUS:85178557243
SN - 0899-7071
VL - 105
JO - Clinical Imaging
JF - Clinical Imaging
M1 - 110028
ER -